Growing demand for CBD-infused products as consumers seek healthy ways to relax and unwind

LONDON, UK / ACCESSWIRE / March 29, 2022 / Eoin Keenan, CEO of Goodrays, tells us how his company, Goodrays, is helping to define the new category by bringing premium, compliant and sustainable CBD products to the market.

Goodrays was born in 2019, after Eoin and his co-founders recognized there was a gap in the market for a true lifestyle brand in the emerging CBD space. With no category leader or clear path to follow, the team decided drinks were the starting point, as they offered the greatest opportunity for widespread adoption of a “new” product and therefore offered the fastest way to conduct trials and advocate for a new ingredient like CBD.

In 2022, as the world emerges from the global pandemic, a significant shift is underway in attitudes towards mental and physical health – wellness, well-being, self-care and connection to the world. natural world being a priority for many, over other more hedonistic pursuits. and means of escape. As a result, the “non-alcoholic and low” category has become the fastest growing sector of the beverage industry, with demand skyrocketing. In 2021, off-premises sales in the United States reached $3.1 billion in the low-alcohol and non-alcoholic wine, beer, and spirits categories, up from just $291 million the previous year.
Along with the growth of “non-alcoholic”, a new category of functional relaxation drinks has emerged, with CBD being a key ingredient in the mix. Products such as good eveningwhich contains 30mg of Colorado-grown CBD per serving, offers the promise of stress relief and mood enhancement with the added benefit of hangover-free mornings.

Goodrays CEO and co-founder Eoin Keenan left Trinity College Dublin after studying international drug policy as part of his undergraduate degree with a personal mission to bring the benefits of cannabinoids – the active compounds derived from the much maligned cannabis plant to a mainstream audience. After graduating, Eoin embarked on a trip to Canada and traveled to California’s famed Emerald Triangle where he gained hands-on experience within the burgeoning legal cannabis industry that had emerged in South America. North at the beginning of the millennium. Medical access has driven the shift in government policy, as cannabis has been proven to improve the quality of life for patients with chronic pain, epilepsy, multiple sclerosis and insomnia, while providing multiple benefits to people undergoing cancer treatment.

In North America, he discovered cannabidiol, or CBD as it’s widely known, the non-toxic compound in cannabis that won’t get you high, but has natural anti-inflammatory, pain-relieving, and stress-relieving qualities. Unbeknownst to him at the time, this discovery would lay the groundwork for the creation of Goodrays.

“Cannabis is perhaps best known for the cannabinoid THC, which is the compound that causes the psychoactive ‘high,’ but there are over 120 other cannabinoids in the plant that interact with the human endocannabinoid system – a system neurological complex that controls appetite, sleep, reproduction and immune response”, explains Eoin. “From my point of view, CBD is the perfect ambassador for cannabis, and cannabinoids more generally, because it is non-intoxicating, non-toxic and offers multiple benefits for the physical and mental well-being of consumers.”

Eoin helped found Europe’s first medical cannabis consultancy, Prohibition Partners, and one of the first emerging industry business conferences, Cannabis Europa. At Prohibition Partners, he worked alongside national governments and global consumer brands to write their cannabis policies and help shape emerging markets for medical and recreational cannabinoid products.

“In any emerging category there will be an element of regulators catching up with the market and that has been the case with the control of CBD products in the UK.” Eoin said. “From the start, we have strived to be the most compliant CBD brand in the UK and have worked closely with the FSA to ensure that every product sold by Goodrays is as safe and compliant as any other product. food or drink.”

Last year in the UK, national grocery chains, restaurant groups and online marketplaces listed CBD product lines to meet growing demand and it is reported that over 8 million shoppers Britons have tried a CBD-infused product in 2020 – 13% of the UK population. “We can clearly see the demand is there,” says Eoin. “The search term ‘CBD’ outranks other high-profile searches such as low-alcohol beer by 27 times, giving an indication of market opportunity.”

Eoin and his team are on track to succeed in their mission to make high-quality CBD products available to everyone through national retailers and they are making strides to become one of the defining lifestyle brands in the category. emergence of healthy and functional cannabinoids. consumables based in Europe.

Three years later, the continued mainstream of CBD is well advanced. Goodrays is sold through traditional outlets such as Selfridges, online marketplaces such as Amazon and has developed a growing direct-to-consumer business driven by influencer marketing and organic media activity social. According to Keenan, Goodrays’ biggest challenge remains educating consumers about the safety and efficacy of a product that for nearly 100 years has been demonized as dangerous despite being one of the most trusted herbal medicines. used in the history of mankind.

“We believe it is our responsibility as a CBD brand to help inform and educate consumers about the history of the plant, to break down barriers, and to communicate how Cannabis Sativa L .is and has been an incredibly useful and important plant.” Eoin said.

good evening The range of natural and healthy cannabidiol products has been designed to offer simple and delicious solutions that allow customers to experience the benefits of CBD – helping people relax and unwind any time of day or night. night.

The CBD market originally emerged in the UK as an offshoot of the health supplement and holistic medicine category, populated by oils and tinctures of varying quality whose origins were often uncertain. From the outset, it was clear that there was significant demand for CBD products, as smaller, artisan brands began to gain traction with people looking for natural alternatives to traditional pharmaceutical pain relievers, antidepressants, and pills. sleeping pills, without the associated side effects or addiction.

Media Contact: Kathy Robinson
E-mail: [email protected]


See the source version on

Source link

Rozella J. Cook